An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Phase 3

Terminated

• Conditions: Huntington Disease
• Interventions: Drug: Dimebon (latrepirdine)

• Registration Number: NCT01085266
• Lead Sponsor: Medivation, Inc.

Brief Summary

An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-02
• Study First Submitted: 2010-03-10
• Study First Submitted QC: 2010-03-10
• Study First Posted: 2010-03-11
• Primary Completion: 2011-06
• Status Verified: 2016-10
• Disposition First Submitted: 2016-10-11
• Disposition First Submitted QC: 2016-10-11
• Last Update Submitted: 2016-10-11
• Disposition First Posted: 2016-10-12
• Last Update Posted: 2016-10-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 362

Inclusion Criteria

• Successful completion of 26 weeks of blinded treatment in the HORIZON study

Read More

Exclusion Criteria

• Any other medical illness or unstable medical condition that may interfere with their ability to comply with study procedures and abide by study restrictions, or may interfere with the ability to interpret safety information.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dimebon (latrepirdine)	Dimebon (latrepirdine)	Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.